SEARCH:   Advanced

Blood, 15 April 2004, Vol. 103, No. 8, pp. 2939-2941. Prepublished online as a Blood First Edition Paper on December 24, 2003; DOI 10.1182/blood-2003-10-3620. This Article Full Text (PDF) All Versions of this Article: 2003-10-3620v1 103/8/2939    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Klion, A. D Articles by Nutman, T. B Search for Related Content PubMed PubMed Citation Articles by Klion, A. D Articles by Nutman, T. B Social Bookmarking                   What's this? Submitted October 23, 2003 Accepted December 14, 2003 Safety and efficacy of the monoclonal anti-interleukin 5 antibody, SCH55700, in the treatment of patients with the hypereosinophilic syndrome Amy D Klion*, Melissa A Law, Pierre Noel, Thomas P Haverty, and Thomas B Nutman Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Heath, Bethesda, MD, USA Department of Laboratory Medicine, Warren Grant Magnusson Clinical Center, National Institutes of Health, Bethesda, MD, USA Schering-Plough Research Institute, Kenilworth, NJ, USA * Corresponding author; email: aklion{at}niaid.nih.gov. Four patients with hypereosinophilic syndrome (HES) refractory to or intolerant of treatment with conventional therapy were treated with a single 1mg/kg dose of SCH55700. SCH55700 was extremely well tolerated. Two of the 4 patients responded with a fall in eosinophil counts to within the normal range within 48 hours of receiving the drug, accompanied by marked improvement in clinical signs and symptoms. Response was not predicted by serum interleukin 5 levels or presence of the FIP1L1/PDGFRA mutation. Eosinophil counts remained suppressed for up to 12 weeks post-treatment; however, exacerbation of symptoms and eosinophilia above baseline levels occurred as drug levels waned. Reinstitution of treatment with monthly SCH55700 led to decreased eosinophilia and symptomatic improvement, albeit to a lesser degree than that seen after the initial dose. These data suggest that anti-IL5 therapy may be useful in the treatment of HES irrespective of the underlying etiology, although the observed rebound eosinophilia and attenuation of response require further study. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: P. Nair, M. M.M. Pizzichini, M. Kjarsgaard, M. D. Inman, A. Efthimiadis, E. Pizzichini, F. E. Hargreave, and P. M. O'Byrne Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia N. Engl. J. Med., March 5, 2009; 360(10): 985 - 993. [Abstract] [Full Text] [PDF] M. E. Rothenberg, A. D. Klion, F. E. Roufosse, J. E. Kahn, P. F. Weller, H.-U. Simon, L. B. Schwartz, L. J. Rosenwasser, J. Ring, E. F. Griffin, et al. Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab N. Engl. J. Med., March 20, 2008; 358(12): 1215 - 1228. [Abstract] [Full Text] [PDF] P. M. O'Byrne The Demise of Anti IL-5 for Asthma, or Not Am. J. Respir. Crit. Care Med., December 1, 2007; 176(11): 1059 - 1060. [Full Text] [PDF] S. K. Frankel, S. D. Groshong, and D. A. Lynch Invited Commentary RadioGraphics, May 1, 2007; 27(3): 637 - 639. [Full Text] [PDF] Y. Yamada, M. E. Rothenberg, A. W. Lee, H. S. Akei, E. B. Brandt, D. A. Williams, and J. A. Cancelas The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease Blood, May 15, 2006; 107(10): 4071 - 4079. [Abstract] [Full Text] [PDF] A. Tefferi, M. A. Elliott, and A. Pardanani Atypical Myeloproliferative Disorders: Diagnosis and Management Mayo Clin. Proc., April 1, 2006; 81(4): 553 - 563. [Abstract] [Full Text] [PDF] A. Tefferi Blood Eosinophilia: A New Paradigm in Disease Classification, Diagnosis, and Treatment Mayo Clin. Proc., January 1, 2005; 80(1): 75 - 83. [Abstract] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020